| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
22.50(B) |
| Last
Volume: |
214,811 |
Avg
Vol: |
443,687 |
| 52
Week Range: |
$274.7 - $517.13 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1207 |
| Guru Rank Value : -1 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
522,527 |
1,074,962 |
1,281,822 |
2,487,848 |
| Total Sell Value |
$253,028,982 |
$487,769,345 |
$551,836,262 |
$907,511,993 |
| Total People Sold |
9 |
10 |
14 |
14 |
| Total Sell Transactions |
58 |
130 |
156 |
341 |
| End Date |
2025-11-13 |
2025-08-12 |
2025-02-11 |
2024-02-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-02-09 |
4 |
AS |
$474.65 |
$10,679,686 |
I/I |
(22,500) |
0 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-02-09 |
4 |
OE |
$117.76 |
$2,872,226 |
I/I |
22,500 |
7,875 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2026-02-05 |
4 |
AS |
$480.92 |
$4,010,940 |
D/D |
(8,300) |
36,781 |
|
1% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2026-02-05 |
4 |
OE |
$146.03 |
$1,212,049 |
D/D |
8,300 |
45,081 |
|
- |
|
| Malcolm Jan |
|
– • – |
2026-02-03 |
4 |
AS |
$474.23 |
$23,712 |
D/D |
(50) |
270 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-02-02 |
4 |
AS |
$470.95 |
$10,596,429 |
I/I |
(22,500) |
0 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-02-02 |
4 |
OE |
$117.76 |
$2,872,226 |
I/I |
22,500 |
7,875 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-26 |
4 |
AS |
$471.91 |
$10,617,932 |
I/I |
(22,500) |
0 |
|
3% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-26 |
4 |
OE |
$117.76 |
$2,872,226 |
I/I |
22,500 |
7,875 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-20 |
4 |
AS |
$456.87 |
$3,659,182 |
I/I |
(7,875) |
0 |
|
4% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-20 |
4 |
OE |
$146.03 |
$1,149,986 |
I/I |
7,875 |
7,875 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-20 |
4 |
AS |
$456.87 |
$6,795,627 |
I/I |
(14,625) |
0 |
|
4% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-20 |
4 |
OE |
$117.76 |
$1,722,240 |
I/I |
14,625 |
14,625 |
|
- |
|
| Malcolm Jan |
|
– • – |
2026-01-16 |
4 |
AS |
$460.98 |
$23,049 |
D/D |
(50) |
320 |
|
4% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2026-01-15 |
4 |
AS |
$468.32 |
$3,900,122 |
D/D |
(8,300) |
36,781 |
|
3% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2026-01-15 |
4 |
OE |
$146.03 |
$1,212,049 |
D/D |
8,300 |
45,081 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-12 |
4 |
AS |
$479.51 |
$10,788,876 |
I/I |
(22,500) |
0 |
|
1% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-12 |
4 |
OE |
$117.76 |
$2,872,226 |
I/I |
22,500 |
7,875 |
|
- |
|
| Causey Christopher |
|
– • – |
2026-01-06 |
4 |
AS |
$510.00 |
$510,000 |
D/D |
(1,000) |
4,190 |
|
-3% |
|
| Causey Christopher |
|
– • – |
2026-01-06 |
4 |
OE |
$119.76 |
$119,760 |
D/D |
1,000 |
5,190 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-05 |
4 |
AS |
$480.68 |
$3,838,085 |
I/I |
(7,875) |
0 |
|
-1% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-05 |
4 |
OE |
$146.03 |
$1,149,986 |
I/I |
7,875 |
7,875 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-05 |
4 |
AS |
$480.68 |
$7,127,877 |
I/I |
(14,625) |
0 |
|
-1% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2026-01-05 |
4 |
OE |
$117.76 |
$1,722,240 |
I/I |
14,625 |
14,625 |
|
- |
|
| Malcolm Jan |
|
– • – |
2026-01-05 |
4 |
AS |
$495.01 |
$24,751 |
D/D |
(50) |
370 |
|
-1% |
|
2262 Records found
|
|
Page 1 of 91 |
|
|
0.28 (0.06%) 
